Organization | Andalusian Health Service

Andalusian Health Service Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2020

NCT04529226

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Andalusian Health Service

Active Ingredients

Drugs in Phase 2 Trials (7)

amisulpride (BARHEMSYS) (1 trial)

clozapine (clozaril) (1 trial)

haloperidol (haldol) (1 trial)

olanzapine (zyprexa) (1 trial)

olive (2 trials)

pimozide (orap) (1 trial)

risperidone (risperdal) (1 trial)

Drugs in Other Trials (1)

oleanolic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Intellectual Disability (Phase 2)

Mental Disorders (Phase 2)

Psychotic Disorders (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 8